Publications by authors named "Robyn L Shea"
Patients with blood cancer continue to have a greater risk of inadequate immune responses following three COVID-19 vaccine doses and risk of severe COVID-19 disease. In the context of the CAPTURE study (NCT03226886), we report immune responses in 80 patients with blood cancer who received a fourth dose of BNT162b2. We measured neutralizing antibody titers (NAbTs) using a live virus microneutralization assay against wild-type (WT), Delta, and Omicron BA.
View Article and Find Full Text PDFArticle Synopsis
- * Out of those tested, 118 had COVID-19, with 94 showing symptoms and only 2 fatalities, revealing high levels of S1-reactive and neutralizing antibodies against the virus.
- * Immune responses varied, particularly with hematological cancer patients showing unique challenges but still managing clinical recovery, highlighting the need for more research on immune durability against different SARS-CoV-2 variants.
Article Synopsis
- The CAPTURE study evaluated COVID-19 immunity in 585 cancer patients after receiving two doses of either BNT162b2 or AZD1222 vaccines, revealing seroconversion rates of 85% for those with solid tumors and 59% for those with hematological malignancies.
- Patients with hematological cancers had significantly lower levels of detectable neutralizing antibodies (NAbT) against SARS-CoV-2 variants compared to those with solid tumors and healthy individuals.
- Previous COVID-19 infections increased NAb responses, particularly against variants, but treatment with anti-CD20 medications correlated with undetectable NAbT, highlighting important considerations for cancer patient management during the pandemic.
CAPTURE (NCT03226886) is a prospective cohort study of COVID-19 immunity in patients with cancer. Here we evaluated 585 patients following administration of two doses of BNT162b2 or AZD1222 vaccines, administered 12 weeks apart. Seroconversion rates after two doses were 85% and 59% in patients with solid and hematological malignancies, respectively.
View Article and Find Full Text PDFArticle Synopsis
- * A high percentage (83%) of patients developed S1-reactive antibodies, but neutralizing antibody levels against virus variants (Alpha, Beta, Delta) were significantly lower, despite stable levels over time.
- * The study indicated that while most patients had detectable SARS-CoV-2-specific T cells and antibody responses, those with blood cancers exhibited weaker immune responses linked to their specific conditions and treatments, yet they still showed some compensatory immune activity.
Introduction Our dried blood spot vitamin D testing service enables members of the public to assess their vitamin D status. Vitamin D has become popular with the media and the general public. We noticed that our direct access service had a higher rate of high to toxic 25-hydroxyvitamin D levels compared with our GP population and we wanted to know why.
View Article and Find Full Text PDFThe identification and exploration of a novel, potent and selective series of N-(3-cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)amide inhibitors of JNK2 and JNK3 kinases is described. Compounds 5a and 11a were identified as potent inhibitors of JNK3 (pIC50 6.7 and 6.
View Article and Find Full Text PDF